Core Viewpoint - Beihai Kangcheng-B (01228) has seen a significant increase in stock price, rising over 12% recently and nearly 20 times year-to-date, indicating strong market interest and potential growth opportunities for the company [1] Group 1: Stock Performance - As of the latest report, Beihai Kangcheng's stock price is at 2.77 HKD, with a trading volume of 50.08 million HKD [1] - The stock has experienced a year-to-date increase of approximately 1900% [1] Group 2: Strategic Partnerships - On August 13, Beihai Kangcheng announced a share subscription agreement with Baiyang Pharmaceutical, where Baiyang will invest 100 million HKD to acquire shares [1] - The partnership includes an exclusive commercialization service agreement, enhancing strategic collaboration between the two companies [1] Group 3: Market Access and Product Approval - Beihai Kangcheng's three products have passed the initial review for the "Commercial Insurance Innovative Drug Directory" set by the National Medical Insurance Administration, which was officially launched on July 11 [1] - The products include Gerunine (Injectable Vira Glycosidase β), Mai Ruibei (Chloramphenicol Oral Solution), and Hai Ruisi (Aidu Sulfate Esterase β Injection), which are expected to accelerate market access [1] - Inclusion in the directory would allow these drugs to receive commercial insurance support, potentially reducing the economic burden on patients and improving product accessibility [1]
港股异动 | 北海康成-B(01228)再涨超12% 公司获百洋医药战略投资 旗下三款产品通过商保创新药目录初审